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Objectives: to evaluate the ability of the diagnostic criteria proposed by Cerero et al in 2010 to perform an early 
diagnose in patients with proliferative verrucous leukoplakia. 
Study Design: retrospective study with patients diagnosed with leukoplakia at Oral Medicine Service at Oral 
Medicine and Surgery Department at Dentistry Faculty at Universidad Complutense of Madrid. 
Results: the criteria were applied in 116 patients, turning positive in 40 cases. Out of these, 24 (60%) had been 
previously diagnosed with PVL. Most frequent criteria were major criteria A and E, concerning lesion’s site and 
histopathology, and minor criteria b and c, concerning sex and smoking habit. 
Conclusions: diagnostic criteria developed by Cerero et al can be a useful tool for an early diagnose of PVL, as in 
60% of the cases, the criteria would have allowed to make an early diagnose of the disease. 
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Introduction
Oral cancer is among the ten most common cancers 
worldwide, although there is a wide geographical vari-
ation in the incidence (1,2). A significant percentage of 
oral cancers are preceded by potentially malignant dis-
orders of the oral mucosa, including leukoplakia. Leu-
koplakia is defined as “a white plaque of questionable 
risk, having excluded (other) known diseases or disor-
ders that carry no increased risk for cancer” (3).
In 1985 Hansen et al described proliferative verrucous 
leukoplakia (PVL) as a long-term progressive condition, 
which develops initially as a white plaque of hyperkera-
tosis that eventually becomes a multifocal disease (4). 
The lesions are slow growing and persistent, as well 
as irreversible and resistant to all forms of treatments, 
with a high recurrence rate (up to 70%). Throughout its 
development is common to find erythematous and/or 
verrucous areas that occasionally progress to verrucous 
carcinoma or squamous cell carcinoma (5).
Usually, PVL diagnosis is made according to Hansen’s 
first definition in 1985, not taking into account the latter 
ones. The inconvenience is that this diagnosis is usu-
ally made once the lesions have evolved, and so they 
have a less favourable prognosis. Therefore, it would be 
important to be able to diagnose early the disease, in or-
der to identify susceptible patients and treat them more 
exhaustively (6).
There are two previous studies, one by Ghazali et al and 
another by Gandolfo et al, that tried to develop a set 
of diagnostic criteria to their respective cases, although 
these are just a transcription of Hansen’s definition 
(7,8). Cerero et al. considered that these criteria were 
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not enough, and proposed another set of criteria based 
not only in Hansen’s definition but also in various find-
ings reported in latter published cases of PVL. These 
criteria can be divided in major and minor criteria: (6)
1. Major Criteria (MC)
a. A leukoplakia lesion with more than two different 
oral sites, usually gingiva, alveolar ridge and palate.
b. Presence of a verrucous area.
c. The lesions have spread or engrossed during the de-
velopment of the disease. 
d. There has been a recurrence in a previously treated 
area.
e. Histopathologically, we can find from simple epithe-
lial hyperkeratosis to verrucous hyperplasia, verrucous 
carcinoma or squamous cell carcinoma, in situ or infil-
trating. 
2. Minor Criteria (mc)
a. An oral leukoplakia lesion that occupies at least 3 cm 
when adding all the affected areas. 
b. The patient is a woman.
c. The patient (male or female) does not smoke. 
d. Disease evolution longer than 5 years. 
In order to establish the diagnosis of PVL, it was suggested 
that two of the following combinations have to exist: three 
major criteria (being E among them) or two major criteria 
(being E among them) plus two minor criteria (6).
This set of diagnostic criteria has not been used and evalu-
ated in any case series, and therefore we do not know their 
real utility and effectiveness. Thus, our objective is to ap-
ply them in a set of patients with oral leukoplakia and eval-
uate their capacity to perform a correct early diagnose of 
PVL. Our second objective will be to analyze the clinical 
characteristics of the cases with positive criteria.  
Material and Methods
-Patients: in this study we included all patients with a 
clinical diagnosis of leukoplakia and a histopathological 
diagnosis that did not exclude leukoplakia. This was a 
retrospective study that analyzed all patients with this 
pathology who were treated at Oral Medicine Service, 
Faculty of Dentistry at Universidad Complutense of 
Madrid between 1984 and 2011. 
-Method: The criteria were applied in all the patients. 
The clinical and histopathological data were obtained 
from their medical records. The first author carried out 
this review manually. Criteria were assessed at the time 
of the leukoplakia diagnosis, one year, and five years 
later. A score of 2 points was given for each major crite-
rion (MC), and 1 point for each minor criterion (mc).  
If the patient had six or more points in their first visit at 
the Oral Medicine Department, they would become part 
of group 1. Later, we would analyse the data obtained 
when applying again the criteria in the annual and five-
years check-up, and we would check the evolution. If the 
patient did not obtain 6 points in the first visit, we would 
check the data at annual check-up, so that they would 
become part of group 2. The same process would be 
done if the patient did not meet the requirements in the 
annual check-up.  We would check the data of 5 years 
after the first diagnosis, and those who had six or more 
points at that moment would became part of group 3. 
Finally, we would check the evolution. 
Also, some clinical data from patients in group 1, 2 and 
3 were recorded: age, sex, tobacco habit, follow-up peri-
od, number of lesions, locations, clinical type, presence 
of pain, biopsies, recurrence of the lesions. 
Results
First of all we selected from the Oral Medicine Service 
Database all those patients who had a clinical diagnosis 
of leukoplakia. We obtained 146 patients, but the inclu-
sion criteria led to the selection of 116 patients. 
Therefore, the diagnosis criteria set described by Cerero 
et al was applied in 116 patients. Criteria were positive 
in 40 patients, distributed as follows: 21 had positive 
criteria right in the moment they were diagnosed with 
leukoplakia (group 1), 8 had positive criteria in the an-
nual check-up (group 2), and 11 at the five-years check-
up (group 3). In every case we observed that the criteria 
would stay the same or increase over time.
Of these 40 patients with positive criteria, 24 (60%) 
had been previously diagnosed with PVL, relying on 
Hansen’s definition. Out of these 24, 18 (75%) obtained 
positive criteria in the moment they were diagnosed 
with leukoplakia or in the annual check-up. It is possible 
that the other 16 patients that have not been diagnosed 
as PVL yet, are on early stages of the disease (Table 1).
Sensitivity (0.88) and specificity (0.82) of these criteria 
was calculated, as well as the positive predictive value 
(0.6) and negative predictive value (0.96), (Table 2).
Most frequent criteria were major criteria A and E, con-
cerning lesion’s location and histopathology, and minor 
criteria b and c, concerning sex and smoking habit, (Ta-
ble 3).
Among all patients with positive criteria we can find 
more women (62,5%). Average age is 62,3 years, and 
there are more non-smoking patients (67,5%%). There 
is an average of 4,4 lesions per patient, being gingiva 
and alveolar ridge the most common locations, followed 
by buccal mucosa. Homogeneous lesions were found 
in 39 patients, while 16 had also verrucous lesions and 
9 eritroleukoplakia lesions. In 22 patients lesions were 
bigger than 3 cm2 and only 5 patients showed pain. 
Number of biopsies varied from 1 to 6; in every case 
there was hyperkeratosis and 50% of them showed signs 
of dysplasia. Three patients had verrucous carcinoma 
and four patients had oral squamous cell carcinoma. 
The follow-up period average was 44 months. The most 
common treatment was surgical removal of the lesions, 
with recurrences in 50% of the cases. 







Yes Yes 24 (60%) + Criteria when the leukoplakia was first diag-
nosed or in the annual check-up18 (75%)
+ Criteria in the five years check- up: 6 (25%)
Yes No 16 (40%) + Criteria when the leukoplakia was first diag-
nosed or in the annual check-up: 11 (68,7%)
+ Criteria in the five years check- up : 5 (31,25%)
Table 1. Positive criteria: patients that meet the diagnostic criteria. PVL: proliferative verrucous leukoplakia.
LVP + LVP -
Positive Criteria 24 16 40
Negative Criteria 3 73 76
27 89 116
Table 2. Sensibility, specifity, positive and negative predictive value data.
Criteria Number of patients with positive criteria
Major Criteria (MC) A (multifocality) 38 (95%)
B (warty areas) 14 (35%)
C (spread of the lesions) 26 (65%)
D (recurrence) 10 (25%) 
E (histopathology) 40 (100%)
Minor Criteria (mc) a (size) 15 (37,5%)
b (sex) 25 (62,5%)
c (tobacco habit) 22 (55%)
d (evolution) 20 (50%)
Table 3. Patients with positive criteria.
Discussion
Proliferative verrucous leukoplakia is considered an 
independent entity from oral leukoplakia, as there are 
differences in its clinical and histopathological char-
acteristics, as well as a more aggressive evolution. The 
malignant transformation rate of this pathology can ap-
pear in up to 70% of the patients, and some studies re-
port even 100% of malignant transformation (5,9). That 
is why an early diagnose can lead in a better prognosis 
for this kind of patients. 
In previously published case series, authors used to 
make PVL diagnosis according to Hansen’s definition. 
Even though this first definition is quite accurate, it has 
not been updated in almost 30 years. In 2010 Cerero et 
al. proposed a set of diagnosis criteria, based not only 
in Hansen’s definition, but also in case series published 
later (6).
Diagnosis criteria proposed by Cerero et al. consist on 
9 criteria, in order to help the clinician to establish a 
suspected diagnosis of PVL as early as possible so we 
can have a better prognosis. 
First criterion refers to multifocality of the lesions, 
which had already been described by Hansen. In our 
study, 38 out of 40 patients with positive criteria had le-
sions in at least 2 different locations, with a media of 4,4 
lesions per patient. More commonly affected areas were 
gingiva and alveolar ridge, followed by buccal mucosa. 
These results are similar to those published by other au-
thors (4,5,10).
Major criteria B and C refer to lesions evolution from 
first diagnosis. Our results show that 11 patients had 
verrucous lesions when we first diagnosed them. In 26 
patients the lesions spread or engrossed during the fol-
low up period. 
About major criterion D, we found recurrence of surgi-
cal removed lesions in at least 50% of the cases. This 
number is lower than those showed by other authors, 
with percentages up to 80%. 
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The last major criterion, E, is essential in order to con-
firm PVL diagnosis. It is a very wide criterion that tries 
to reflect from a histopathological point of view the nat-
ural evolution of the disease (6). In our study only seven 
patients have developed so far some kind of carcinoma. 
Three of them had lesions that evolved to verrucous 
carcinoma and four to oral squamous cell carcinoma. 
The average time to appearance of the carcinoma was 
almost 4 years (3,77 years). 
About minor criterion, the first one refers to the leu-
koplakia lesions size. In PVL, Cerero et al consider 
that the presence of multiple lesions in different sites 
is more relevant than the size of the lesion itself and 
therefore, they consider these criteria as a minor one. In 
our study, 55% of the patients had lesions bigger than 3 
cm2 when adding all the affected areas. Second minor 
criterion refer to patient’s sex. Most PVL studies report 
a higher prevalence of this pathology in women; we can 
even find a 4:1 ratio (4,5,11). Other studies show fewer 
differences between sexes, but always in smaller case 
series (9,12).  
There are also discrepancies among different authors 
regarding tobacco habit. Although there is a consensus 
about tobacco not having a significant influence on the 
disease, there is a big variety in the percentages we find 
in different studies. This could be related to the deci-
sion to consider or not former smokers as smokers. In 
our study, we included former smokers for more than 
10 years as non-smoker patients, basing our decision in 
several previous studies that state that after that time, 
former smoker patients have the same odds of suffer-
ing oral cancer than non-smoker patients (13). In our 
study, 18 patients where smokers or former smokers for 
less than 10 years, and therefore did not meet criterion 
c. This percentage (45%) is similar to those shown by 
other authors, like Gandolfo et al (37%) (8).
Finally, we should consider the disease evolution, as 
PVL is considered a long-term pathology. Even though 
it is complicated to determine the exact moment when 
the lesions appeared, most of case series published re-
port that evolution period is longer than 5 years.  
Recently Carrad et al. (2013) published a critical ap-
praisal of these diagnostic criterion (14). In their opin-
ion, major criteria A should not include keratinized 
mucosa as the most frequently involved site in PVL, 
but considerer that any site of the oral cavity may be 
involved. However, in our study, and in all but one of the 
case series included in Cerero et al. study, we found that 
most of the lesions would appear in keratinized mucosa 
(gingiva, alveolar ridge and palate).  About major cri-
terion E, we consider that even though that histopatho-
logy description is not limited to PVL, it can be useful 
to discard different pathologies, and therefore it should 
be maintained as diagnostic criterion. About the higher 
prevalence in women and the absence of tobacco habit 
should be kept in our opinion as minor criterion, be-
cause even if there are not definitive data about this, 
we can find important differences among percentages 
found in leukoplakia case series and PVL case series 
(15). Finally, we consider that the modified diagnostic 
criteria can be useful to diagnose a PVL that is already 
in an advance stage, but maybe they are not enough if 
we want to make an early diagnose, and foresee if a sin-
gle leukoplakia has the risk to develop PVL. 
Out of our 40 patients that met the diagnostic criterion-
proposed by Cerero et al. 24 of them (60%) had a previ-
ous diagnose of PVL. In all of them we found that the 
lesions spread and enlarged during their development. 
Out of these 24 patients, 18 of them met the diagnostic 
criteria either on the first time they came to our clinic 
or in the annual check-up. Therefore, we consider that 
these criteria may be useful to make an early diagnose 
of PVL. 
In the remaining patients the lesions have not changed 
in the successive check-ups, but we cannot assure that 
they will not develop PVL in the future. In our opin-
ion, the fact that 40% of patients that met the diagnos-
tic criteria did not develop PVL, does not detract the 
criteria utility, since its implementation is simple and 
non-traumatic, and allow us to make a more appropriate 
track to our patients.
We found interesting the presence of both lichen planus 
and PVL lesions associated in this kind of patients. This 
make us think about the possibility of not making a cor-
rect differential diagnosis between these two patholo-
gies or maybe about the coexistence of the lesions (16).
In conclusion, we consider that the diagnostic criteria 
developed by Cerero et al. allow us to make an early 
diagnose of PVL, so that 60% of the patients that meet 
the criteria end up developing the disease. Most com-
mon criteria when the first diagnose is made are major 
criterion A and E and minor criterion b and c. Thereby, 
we consider that the clinician should suspect of having 
a patient with PVL when having a patient that is a non-
smoker with lesions in multiple locations and with an 
histopathological diagnosis compatible with leukopla-
kia. Likewise, it is necessary to assess the presence of 
warty lesions, lesions that have thickened and spread 
over time, and lesions with a long-term evolution.    
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